Evidence method
Level · gp.fundamentals.debt_to_revenue
301.45% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Jun 30, 2022
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-22-000020General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
7.14% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-54.63% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
1.93% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
39.58% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
84.86% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-85.26% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
91.50% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
13.55% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 317.32%
- Current
- 301.45%
- Delta
- -15.86%
- Previous
- 8.37%
- Current
- 7.14%
- Delta
- -1.23%
- Previous
- -80.27%
- Current
- -54.63%
- Delta
- 25.64%
- Previous
- 20.10%
- Current
- 1.93%
- Delta
- -18.17%
- Previous
- 36.82%
- Current
- 39.58%
- Delta
- 2.76%
- Previous
- 89.00%
- Current
- 84.86%
- Delta
- -4.14%
- Previous
- -68.80%
- Current
- -85.26%
- Delta
- -16.46%
- Previous
- 79.67%
- Current
- 91.50%
- Delta
- 11.84%
- Previous
- 13.74%
- Current
- 13.55%
- Delta
- -0.18%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_INCREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.